Material Information - Announcement of the Topline Results from the Phase I Clinical Trial of PharmaEssentia's Long-acting GCSF, P2203

PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting

Material Information - The Board Approved to Set Aside the Partial Final Award on the ICC Arbitration Against AOP, and to Request Suspension of the Second Phase of Proceedings

PharmaEssentia April 2025 Revenue Report

Material Information - Update on the Company's IND Application of Phase I Clinical Trial of TCRT-ESO-A2-TW in Patients with Advanced Solid Tumors

PharmaEssentia March 2025 Revenue Report

Material Information - The Company Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2b) for PV in Vietnam

PharmaEssentia Presents at the J.P. Morgan 43rd Annual Healthcare Conference

Material Information - Update on the Company's IND Application ofPhase I Clinical Trial of TCRT-ESO-A2-TW in Patientswith Advanced Solid Tumors to TFDA

PharmaEssentia to Participate in Upcoming Investor Conferences

Patient Perspectives

Hear Buzz tell the story of his PV journey.

Patient Perspectives

Hear her story, including how she has learned to cope with her PV through music.

Patient Perspectives

Hear Patti's story

Patient Perspectives

Hear Steven's story

PHARMAESSENTIA TO HOST INVESTOR DAY IN NEW YORK CITY ON NOVEMBER 30, 2022